利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.021 秒)

    NANOPARTICLES AND THEIR USE IN CANCER THERAPY
    21.
    发明公开
    NANOPARTICLES AND THEIR USE IN CANCER THERAPY 审中-公开
    纳米颗粒及其在癌症治疗中的应用

    公开(公告)号：EP3237016A1

    公开(公告)日：2017-11-01

    申请号：EP15820158.2

    申请日：2015-12-22

    申请人： Midatech Ltd

    发明人： GOLDING, Jon ,  WILLIAMS, Phillip ,  ROSKAMP, Meike

    IPC分类号： A61K47/50 ,  A61P35/00

    CPC分类号： A61K33/24 ,  A61K9/0014 ,  A61K47/549 ,  A61K47/6923 ,  A61K47/6929 ,  A61N5/10 ,  A61N2005/1098

    摘要： The present invention provides a nanoparticle comprising a core comprising a metal; and a corona comprising a plurality of ligands covalently linked to the core, the plurality of ligands including at least a first species of ligand comprising an ethylene glycol portion and an amine group and at least a second species of ligand comprising a carbohydrate group, for use in a method of treating a cancer, particularly skin cancer, in a mammalian subject. Also disclosed are methods of treatment by administering the nanoparticles alone or in combination with radiotherapy.

    摘要翻译： 本发明提供了包含含有金属的核的纳米颗粒; 以及包含共价连接至所述核的多个配体的电晕，所述多个配体包括至少第一种包含乙二醇部分和胺基的配体和至少第二种包含碳水化合物基团的配体种类以供使用 在哺乳动物对象中治疗癌症，特别是皮肤癌的方法中。 还公开了通过单独施用纳米颗粒或与放疗组合施用的治疗方法。

    NANOPARTICLE TUMOUR VACCINES
    23.
    发明公开
    NANOPARTICLE TUMOUR VACCINES 审中-公开
    纳米粒子肿瘤疫苗

    公开(公告)号：EP2753361A1

    公开(公告)日：2014-07-16

    申请号：EP12768753.1

    申请日：2012-09-07

    申请人： Midatech Ltd. ,  Immunotope, Inc.

    发明人： RADEMACHER, Thomas ,  PHILIP, Ramila

    IPC分类号： A61K47/48 ,  A61P35/00

    CPC分类号： A61K9/141 ,  A61K39/0011 ,  A61K47/6923 ,  A61K47/6929

    摘要： The present invention provides a vaccine for the prophylactic or therapeutic treatment of a tumour in a mammalian subject, as well as methods of using the vaccine, including in treatment of tumours and in generating a CTL response. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier, salt or diluent. The nanoparticles comprise a core comprising a metal and/or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that iscovalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises an epitopic peptide that is covalently linked to the core via a second linker, said second linker comprising a peptide portion and a non-peptide portion, wherein said peptide portion comprises the sequence X
    1 X
    2 Z
    1 , wherein: X
    1 is an amino acid selected from A and G; X
    2 is an amino acid selected from A and G; and Z
    1 is an amino acid selected from Y and F, and wherein said epitopic peptide forms at least a portion of or is derived from a Tumour-Associated Antigen (TAA).

    SUSTAINED RELEASE ENCAPSULATED NANOPARTICLES
    30.
    发明公开
    SUSTAINED RELEASE ENCAPSULATED NANOPARTICLES 审中-公开
    持续释放封装纳米颗粒

    公开(公告)号：EP3217958A1

    公开(公告)日：2017-09-20

    申请号：EP15794158.4

    申请日：2015-11-11

    申请人： Midatech Ltd ,  Midatech Pharma (Wales) Limited

    发明人： WILLIAMS, Phillip ,  GROVES, Rhian ,  PALMER, Daniel

    IPC分类号： A61K9/00 ,  A61K47/34 ,  A61K9/16 ,  A61K47/50 ,  A61K9/51

    摘要： The present invention provides a microparticle comprising at least one biocompatible polymer, the microparticle encapsulating at least one nanoparticle, the nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise at least one carbohydrate and/or glutathione. The nanoparticle may additionally comprise a biologically active agent or detectable label covalently linked or non-covalently bound to said corona and/or said core. Also disclosed are pharmaceutical compositions comprising the microparticles, processes for their production and uses of the microparticles in methods of therapy.

    摘要翻译： 本发明提供包含至少一种生物相容性聚合物的微粒，所述微粒包封至少一个纳米粒子，所述纳米粒子包含：（i）包含金属和/或半导体的核; 和（ii）包含多个共价连接至核的配体的冠，其中所述配体包含至少一种碳水化合物和/或谷胱甘肽。 纳米颗粒可另外包含与所述电晕和/或所述核共价连接或非共价结合的生物活性剂或可检测标记。 还公开了包含微粒的药物组合物，其制备方法和微粒在治疗方法中的用途。